Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

Five things for pharma marketers to know: Wednesday, August 19

Five things for pharma marketers to know: Wednesday, August 19

Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations

Amgen settles off-label case with states

Amgen settles off-label case with states

State attorneys general accused the drugmaker of violating state consumer protection laws.

Five things for pharma marketers to know: Tuesday, August 18

Five things for pharma marketers to know: Tuesday, August 18

Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

What to expect in wake of the Amarin ruling: more truthful off-label talk from pharma

What to expect in wake of the Amarin ruling: more truthful off-label talk from pharma

But don't expect the floodgates to open. Marketers still have to take a legal route to promote such information.

Five things for pharma marketers to know: Friday, August 14

Five things for pharma marketers to know: Friday, August 14

GSK studying Breo Ellipta in lung-cancer patients; researchers develop strains of yeast for painkillers in a lab; Wolters Kluwer acquires CME provider

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.

We're searching for 2015's Outstanding Contributor to Healthcare

We're searching for 2015's Outstanding Contributor to Healthcare

Know a very special person or group making extraordinary contributions to public health? We want to hear from you.

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.

Everyday Health expects growth from consolidated offerings and specialty brands

Everyday Health expects growth from consolidated offerings and specialty brands

The media company said orphan drugs and specialty medicines, like PCSK9 inhibitors, will drive the company's business going forward.

Five things for pharma marketers to know: Wednesday, August 12

Five things for pharma marketers to know: Wednesday, August 12

J&J turns to digital marketing in China; GSK closes North Carolina facility; Kim Kardashian West's promotion of Diclegis increased online conversations about the brand

Everyday Health buys hospital marketing firm

Everyday Health buys hospital marketing firm

The company acquired Tea Leaves Health for $30 million to diversify its business.

Five things for pharma marketers to know: Tuesday, August 11

Five things for pharma marketers to know: Tuesday, August 11

"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling

How Direct Marketing Must Adapt in Today's Healthcare System

How Direct Marketing Must Adapt in Today's Healthcare System

By breaking down traditional organizational silos to bring together the chief medical officer and the chief marketing officer, companies can unite the forces of clinical best practices with direct-to-consumer response marketing.

Judge grants relief to Amarin in off-label case

Judge grants relief to Amarin in off-label case

The decision, a setback for the FDA, allows the drugmaker to move forward with plans to legally promote some off-label information.

The MM&M Weekly News Quiz: August 7

The MM&M Weekly News Quiz: August 7

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Allergan sales rise on "strong" DTC advertising

Allergan sales rise on "strong" DTC advertising

Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.

Five things for pharma marketers to know: Thursday, August 6

Five things for pharma marketers to know: Thursday, August 6

AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Findings of a new report suggest ways pharma should rethink its commercial and R&D decisions in light of improved survival rates associated with some cancers.

Astellas to use rugby to promote prostate-cancer awareness

The drugmaker, which sells prostate-cancer treatment Xtandi, wants social-media users to help spread the word about the disease

Five things for pharma marketers to know: Wednesday, August 5

Five things for pharma marketers to know: Wednesday, August 5

The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information

Firms promising Rx savings deepen ties to EHR platforms

Recent deals show these companies are expanding their EHR networks, and the number of physicians who gain access to copay coupons, vouchers and other forms of assistance.

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.

Five things for pharma marketers to know: Tuesday, August 4

Five things for pharma marketers to know: Tuesday, August 4

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Healthcare reimagined: Fortner finesses McKesson's bold vision

Healthcare reimagined: Fortner finesses McKesson's bold vision

From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

The MM&M Weekly News Quiz: July 31

The MM&M Weekly News Quiz: July 31

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 31

Five things for pharma marketers to know: Friday, July 31

Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment

Wunderman Health acquires ABS Creative

The New York-based agency took a majority stake in the full-service healthcare agency.

Sanofi launches DTC campaign for Afrezza

Sanofi launches DTC campaign for Afrezza

The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

More patients are seeking treatments with even fewer side effects and shorter durations.

Turing names J&J vet for chief comms role

Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Graphic: the new hepatitis-C drug market

Graphic: the new hepatitis-C drug market

View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

MMC hires first CMO

The integrated agency's pharmaceutical business now brings in half its billings.

Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

Therapeutic Focus: Oncology

Therapeutic Focus: Oncology

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment

FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

BMS US sales are down, despite growing Opdivo adoption

BMS US sales are down, despite growing Opdivo adoption

Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.

Five things for pharma marketers to know: Thursday, July 23

Five things for pharma marketers to know: Thursday, July 23

Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

Praluent's FDA review looms, but questions persist

Praluent's FDA review looms, but questions persist

A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Orchestrating Key Stakeholder Engagement for Launch Success

Orchestrating Key Stakeholder Engagement for Launch Success

The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.

Allergan debuts #ActuallySheCan campaign

Allergan debuts #ActuallySheCan campaign

The new campaign seeks to connect with millennial women.

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

CMS updates CME guidance

CMS updates CME guidance

New rules will require manufacturers to report some indirect payments made to physicians for CME activities.

The FDA seeks comments on DTC ad perception

The agency plans to research extrinsic factors that influence the way a patient perceives a drug.

Five things for pharma marketers to know: Monday, July 20

Five things for pharma marketers to know: Monday, July 20

Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week

Five things for pharma marketers to know: Friday, July 17

Five things for pharma marketers to know: Friday, July 17

Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker

NORD and University of Maryland partner for rare-disease research training

The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.

Patients expect pharma will boost engagement

Patients expect pharma will boost engagement

The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.

Pricing pressure drives pharma collaborations, report says

Pricing pressure drives pharma collaborations, report says

The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.

New Sanofi CEO reorganizes company

The restructuring is expected to simplify the drugmaker's organization.

Five things for pharma marketers to know: Wednesday, July 15

Five things for pharma marketers to know: Wednesday, July 15

Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands

J&J prepares to defend Remicade market share

J&J prepares to defend Remicade market share

Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.

Private equity firm acquires CME provider

Vesey Street Capital Partners acquired Atlanta-based CME provider Imedex.

Five things for pharma marketers to know: Tuesday, July 14

Five things for pharma marketers to know: Tuesday, July 14

The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices

More than 400 drugs in development for neurological disorders

PhRMA and the Epilepsy Foundation said 50-million Americans are affected by disorders such as Alzheimer's disease and multiple sclerosis.

Five things for pharma marketers to know: Monday, July 13

Five things for pharma marketers to know: Monday, July 13

Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients

Five things for pharma marketers to know: Friday, July 10

Five things for pharma marketers to know: Friday, July 10

21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card

House expected to vote on 21st Century Cures

House expected to vote on 21st Century Cures

The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.

Five things for pharma marketers to know: Thursday, July 9

Five things for pharma marketers to know: Thursday, July 9

Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort

AdComm Preview: Eli Lilly's lung-cancer drug

AdComm Preview: Eli Lilly's lung-cancer drug

An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

Five things for pharma marketers to know: Wednesday, July 8

Five things for pharma marketers to know: Wednesday, July 8

CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen

Insurance trade group says new HCV drugs could cost California billions

An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.

Five things for pharma marketers to know: Tuesday, July 7

Five things for pharma marketers to know: Tuesday, July 7

Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher

Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Sermo expands to Canada in global expansion

Sermo expands to Canada in global expansion

The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.

Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Five things for pharma marketers to know: Monday, June 22

Five things for pharma marketers to know: Monday, June 22

AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.

Grand Prix drought ends, but questions persist

Grand Prix drought ends, but questions persist

The inspirational value is clear for Lions Health attendees, but there is still confusion about what good looks like for branded pharma campaigns, and how the US fits in.

Pharma at Cannes: C'est la Vie

Pharma at Cannes: C'est la Vie

It's not only a venue to gain creative inspiration, but a good place to scout talent, and there are no lack of strategic meetings underway in Cannes.

Novartis exec: Pharma culture can be stumbling block to creativity

Novartis exec: Pharma culture can be stumbling block to creativity

It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca's "Take it from a Fish" took the top prize.

Five things for pharma marketers to know: Friday, June 19

Five things for pharma marketers to know: Friday, June 19

Teva loses Copaxone patent suit; Oncologists at Memorial Sloan Kettering Cancer Center developed cancer drug cost calculator; Bayer will invest $4.5 billion in R&D in the coming year.

19 US entries shortlisted at Lions Health

19 US entries shortlisted at Lions Health

The Lions Health award winners will be announced later Friday at an event in Cannes, France.

Doximity expands professional reach

Its alliance with the Society of Hospital Medicine will expand the network's reach among medical professionals.

Takeda revamps commercial org to synch with R&D

Takeda revamps commercial org to synch with R&D

The Japan-based drugmaker recast its global organization in hopes of ensuring that emerging molecules make a smoother transition to market.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.